Molecular Decisions (MDI) is an oncology diagnostic company focused on developing proteomics-based assays that provide physicians with real-time information to direct their clinical decision-making and provide the best-personalized care. Our unique proteomic platform measures modifications occurring to protein targets of therapeutic agents which can predict therapeutic drug efficacy and positive patient outcomes.